Several other equities research analysts have also commented on AUPH. Zacks Investment Research lowered shares of Aurinia Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 16th. HC Wainwright reaffirmed a buy rating and issued a $25.00 price target on shares of Aurinia Pharmaceuticals in a report on Tuesday, June 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $15.65.
Shares of AUPH opened at $6.10 on Friday. Aurinia Pharmaceuticals has a 1-year low of $5.06 and a 1-year high of $7.85. The firm’s fifty day moving average is $6.33.
A number of large investors have recently bought and sold shares of the business. NEA Management Company LLC boosted its holdings in Aurinia Pharmaceuticals by 7.6% in the first quarter. NEA Management Company LLC now owns 5,172,683 shares of the biotechnology company’s stock valued at $33,622,000 after purchasing an additional 364,200 shares during the last quarter. FMR LLC raised its position in shares of Aurinia Pharmaceuticals by 7.9% in the fourth quarter. FMR LLC now owns 5,049,740 shares of the biotechnology company’s stock worth $34,439,000 after acquiring an additional 368,781 shares during the period. Redmile Group LLC acquired a new position in shares of Aurinia Pharmaceuticals in the first quarter worth about $2,101,000. Creative Planning raised its position in shares of Aurinia Pharmaceuticals by 24.5% in the first quarter. Creative Planning now owns 208,700 shares of the biotechnology company’s stock worth $1,357,000 after acquiring an additional 41,043 shares during the period. Finally, Swiss National Bank raised its position in shares of Aurinia Pharmaceuticals by 14.0% in the second quarter. Swiss National Bank now owns 111,800 shares of the biotechnology company’s stock worth $738,000 after acquiring an additional 13,700 shares during the period. 32.56% of the stock is currently owned by institutional investors.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Featured Story: Why do company’s buyback their stock?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.